A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation.
about
Risk of diarrhoea in a long-term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the UGT1A8 2 variant alleleMycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity.Reasons for dose reduction of mycophenolate mofetil during the first year after renal transplantation and its impact on graft outcome.Pharmacokinetics and pharmacodynamics of intensified versus standard dosing of mycophenolate sodium in renal transplant patients.Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients.The correlation between the expression of genes involved in drug metabolism and the blood level of tacrolimus in liver transplant receiptsExpression of IMPDH mRNA after mycophenolate administration in male volunteers.The CLEAR study: a 5-day, 3-g loading dose of mycophenolate mofetil versus standard 2-g dosing in renal transplantation.Performance of the new mycophenolate assay based on IMPDH enzymatic activity for pharmacokinetic investigations and setup of Bayesian estimators in different populations of allograft recipients.Population pharmacokinetics of mycophenolic acid and metabolites in patients with glomerulonephritis.Inosine 5'-monophosphate dehydrogenase 1 haplotypes and association with mycophenolate mofetil gastrointestinal intolerance in pediatric heart transplant patients.Sirolimus: a comprehensive review.Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part IMycophenolic acid formulations in adult renal transplantation - update on efficacy and tolerability.Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoringUGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients.Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies.From pharmacokinetics to pharmacogenomics: a new approach to tailor immunosuppressive therapy.Population pharmacokinetic analysis of mycophenolic acid in renal transplant recipients following oral administration of mycophenolate mofetil.Mycophenolic acid pharmacokinetics and related outcomes early after renal transplantA comparison of the effect of ciclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients.Investigation on pharmacokinetics of mycophenolic acid in Chinese adult renal transplant patientsPharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation.Current and future immunosuppressive strategies in renal transplantation.Two inhibitors of DNA-synthesis lead to inhibition of cytokine production via a different mechanism.Therapeutic monitoring of immunosuppressant drugs. Where are we?Pharmacokinetic principles of immunosuppressive drugs.Time-dependent clearance of mycophenolic acid in renal transplant recipientsEffects of gastric emptying on oral mycophenolic acid pharmacokinetics in stable renal allograft recipients.Immunosuppressive drug monitoring - what to use in clinical practice today to improve renal graft outcome.Population pharmacokinetics of mycophenolic acid and dose optimization with limited sampling strategy in liver transplant children.Individualization of mycophenolate mofetil dose in renal transplant recipients.Association of mycophenolic acid dose with efficacy and safety events in kidney transplant patients receiving tacrolimus: an analysis of the Mycophenolic acid Observational REnal transplant registry.Therapeutic drug monitoring of mycophenolic acid: does it improve patient outcome?Genetic determinants of mycophenolate-related anemia and leukopenia after transplantation.Nonrelapse mortality and mycophenolic acid exposure in nonmyeloablative hematopoietic cell transplantationInosine monophosphate dehydrogenase (IMPDH) activity as a pharmacodynamic biomarker of mycophenolic acid effects in pediatric kidney transplant recipients.Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease.Mycophenolate mofetil in the treatment of lupus nephritis.Mycophenolate pharmacokinetics and pharmacodynamics in belatacept treated renal allograft recipients - a pilot study
P2860
Q24595480-CA6FFF0C-A563-4105-82DC-5FE8EC41F7AAQ33370034-0192BE2A-280F-4D23-8E94-76959AEF11A5Q33408239-612A071C-D14D-42DE-BA93-07A4A5AE800FQ33684048-C22D8774-14BC-4948-A450-C5D10F13E53BQ33764989-A9E52A52-19A2-48E9-86BD-4233D181A842Q33793971-88B04D86-531C-4084-8D62-9A5ABF116CD9Q33912025-F0130990-4B5F-43A3-9ECC-98FB8C82DDA0Q33944794-CE08130E-7168-446D-B2AE-96273A49F798Q34077882-26C3C9EE-3E3A-4F61-9738-1E39EB9CB341Q34152549-807C87D3-F9E8-4829-B76C-32B7D444A1F2Q34203809-FFF61B6D-1887-4981-A04C-9DEB78159D75Q34515537-B7AC2FAE-34FA-44A5-B849-62EBA6E8F4FBQ34610933-CF0C8B17-1104-4781-A1EC-F14286D2035EQ34611858-542067CB-1DCA-4A56-A737-9CE443162BD4Q34858098-22669EBC-DD74-4D07-83A5-89E1C3D1791BQ34984788-56F66FBA-D2D7-4E4B-AF10-2D0F9260A553Q35129548-87C59A33-D2B8-4455-B52D-0312D12E3248Q35666588-D246443E-FA42-4FFE-A74F-69238CE9B204Q35825497-51E58BBF-6B33-4003-80FD-08F567DED6C1Q35826828-AA400CD4-0C80-4FA3-818C-762C0607392CQ35827807-99BCD210-4019-4CC4-B0C3-1A974E819432Q35827831-7F7D755A-4966-48EF-85FE-1B850EED8523Q35848175-6B4C4D38-746B-4BC2-8A9F-DC3C89F85B41Q35906315-6FB04823-3CA4-4804-B163-89516AC5A45BQ35967186-FF186968-91FA-4CB2-8419-578A5E98901AQ35970335-9F447A37-5051-46DE-ABFB-60A9E5D9C46EQ36006086-D23F3A9B-5683-4096-8E56-16B05D49C6EAQ36024478-0A1C3685-4C18-481B-AE74-F7E00F215232Q36025085-376F45AC-057D-4C33-8554-93289844240CQ36029868-011AD0D7-A7B7-4B03-A688-7CE35706B45DQ36336060-EE8A5851-FF78-47CF-8559-6B5797322E39Q36407345-29C197FC-055B-4E10-B55B-F877E16DC2F0Q36566866-5EC44737-34E1-4246-BF9D-5C74B39F1432Q36788423-641E839B-3402-45B3-AA58-43AF884F17E8Q37013588-914965D6-138E-46C0-A614-01D1A2509909Q37038889-7F0ED53E-D579-4044-A262-398D46A051A7Q37161962-1BD65A80-E9D8-4EFD-ABD1-7916F78B6172Q37201939-203D265E-2809-4216-B48D-AE995670DB7EQ37290624-8492513C-4BC4-4D10-A0B2-83EB7DB525F7Q37299171-F3A7B214-35C1-44AF-9213-89209E66525A
P2860
A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
A randomized double-blind, mul ...... after kidney transplantation.
@en
A randomized double-blind, mul ...... after kidney transplantation.
@nl
type
label
A randomized double-blind, mul ...... after kidney transplantation.
@en
A randomized double-blind, mul ...... after kidney transplantation.
@nl
prefLabel
A randomized double-blind, mul ...... after kidney transplantation.
@en
A randomized double-blind, mul ...... after kidney transplantation.
@nl
P2093
P1433
P1476
A randomized double-blind, mul ...... after kidney transplantation.
@en
P2093
A J Nicholls
G A Verpooten
J P Squifflet
J W de Fijter
L B Hilbrands
M T Navarro
T van Gelder
P304
P356
10.1097/00007890-199907270-00018
P577
1999-07-01T00:00:00Z